Biotron Ltd. | |
Stock Exchange | Australian Stock Exchange |
EPS |
AUD0 |
Market Cap |
AUD44.68 M |
Shares Outstanding |
595.71 M |
Public Float |
592.79 M |
Address |
56 Delhi Road North Ryde New South Wales (NSW) 2113 Australia |
Employees | - |
Website | http://www.biotron.com.au |
Updated | 07/08/2019 |
Biotron Ltd. is a clinical stage Australian biotechnology company. It engages in developing and commercializing a novel small molecule approach that has the potential to treat a number of serious viral diseases. The company's technology targets viroporin proteins, which are key to enabling the pathogenicity of a number of viruses including hepatitis C, HIV-1, Dengue, Zika, Influenza and Respiratory Syncytial Virus. |